159 related articles for article (PubMed ID: 35227898)
1. Effectiveness of different treatment strategies in elderly patients with glioblastoma: An evidence map of randomized controlled trials.
Ma W; Sheng X; Li G; Wei Q; Zhou Z; Qiu X
Crit Rev Oncol Hematol; 2022 May; 173():103645. PubMed ID: 35227898
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
3. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
4. Tumour Treating Fields (TTFs) for recurrent and newly diagnosed glioblastoma multiforme.
Mirza FA; Shamim MS
J Pak Med Assoc; 2018 Oct; 68(10):1543-1545. PubMed ID: 30317361
[TBL] [Abstract][Full Text] [Related]
5. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
6. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.
Mittal S; Klinger NV; Michelhaugh SK; Barger GR; Pannullo SC; Juhász C
J Neurosurg; 2018 Feb; 128(2):414-421. PubMed ID: 28298023
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
8. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
Yang J; Shi Z; Liu R; Wu Y; Zhang X
Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.
Yin AA; Zhang LH; Cheng JX; Dong Y; Liu BL; Han N; Zhang X
PLoS One; 2013; 8(9):e74242. PubMed ID: 24086323
[TBL] [Abstract][Full Text] [Related]
10. [Current status and prospect in the treatment of glioblastoma].
Jiang HH; Lin S
Zhonghua Wai Ke Za Zhi; 2020 Jan; 58(1):70-74. PubMed ID: 31902174
[TBL] [Abstract][Full Text] [Related]
11. Optimal adjuvant therapy in elderly glioblastoma: results from a systematic review and network meta-analysis.
Kalra B; Kannan S; Gupta T
J Neurooncol; 2020 Jan; 146(2):311-320. PubMed ID: 31894517
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Carter TC; Medina-Flores R; Lawler BE
Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
[TBL] [Abstract][Full Text] [Related]
13. Radiation and Immunotherapy in High-grade Gliomas: Where Do We Stand?
Reznik E; Smith AW; Taube S; Mann J; Yondorf MZ; Parashar B; Wernicke AG
Am J Clin Oncol; 2018 Feb; 41(2):197-212. PubMed ID: 28906259
[TBL] [Abstract][Full Text] [Related]
14. Progress and prospect in tumor treating fields treatment of glioblastoma.
Liu S; Shi W; Zhao Q; Zheng Z; Liu Z; Meng L; Dong L; Jiang X
Biomed Pharmacother; 2021 Sep; 141():111810. PubMed ID: 34214730
[TBL] [Abstract][Full Text] [Related]
15. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials.
Lv L; Huang J; Xi H; Zhou X
Int Immunopharmacol; 2020 Jun; 83():106336. PubMed ID: 32213460
[TBL] [Abstract][Full Text] [Related]
17. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
18. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
19. Timing of Chemoradiation in Newly Diagnosed Glioblastoma: Comparative Analysis Between County and Managed Care Health Care Models.
Toor H; Savla P; Podkovik S; Patchana T; Ghanchi H; Kashyap S; Tashjian V; Miulli D
World Neurosurg; 2021 May; 149():e1038-e1042. PubMed ID: 33476782
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.
Cabrera AR; Cuneo KC; Vredenburgh JJ; Sampson JH; Kirkpatrick JP
J Natl Compr Canc Netw; 2012 Jun; 10(6):695-9. PubMed ID: 22679114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
